Sclerostin Binding Agents for Bone Resorption and Density Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for bone-related disorders such as osteoporosis often fail to effectively inhibit bone resorption while simultaneously promoting bone formation, leading to potential adverse side effects and instability in calcium levels.
Innovation Solution
Administering sclerostin inhibitors, particularly sclerostin binding agents, to reduce markers of bone resorption and increase markers of bone formation, thereby uncoupling the processes to enhance bone mineral density and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If current therapies are used to treat bone-related disorders, then bone mineral density may be improved, but calcium level stability deteriorates and adverse side effects occur
Solution Approach 1:
The patent introduces sclerostin binding agents as intermediary molecules that specifically target and neutralize sclerostin, a protein that inhibits bone formation. By using this intermediary approach, the therapy achieves bone mineral density improvement without the destabilizing effects on calcium levels seen with conventional treatments, as the mechanism acts through the specific Wnt signaling pathway rather than general calcium metabolism disruption
2Strength
If bone resorption inhibition is pursued, then bone formation may be promoted, but adverse side effects increase
Solution Approach 1:
The patent changes the therapeutic parameter from general bone metabolism modulation to specific sclerostin pathway inhibition. By targeting the molecular level parameter (sclerostin binding) rather than broader physiological parameters, the therapy promotes bone formation through enhanced Wnt signaling while avoiding the adverse side effects associated with non-specific bone metabolism interference
Data Source
AI summary
The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more bone resorption marker levels, administering a sclerostin binding agent, then measuring the bone resorption marker levels. Also provided is a method of increasing bone mineral density; a method of ameliorating the effects of an osteoclast-related disorder; a method of treating a bone-related disorder by maintaining bone density; and a method of treating a bone-related disorder in a human suffering from or at risk of hypocalcemia or hypercalcemia, a human in which treatment with a parathyroid hormone or analog thereof is contraindicated, or a human in which treatment with a bisphosphonate is contraindicated.